Telomir Pharmaceuticals financials
$1.17−2.50%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$1.8M | -$1.0M | -$2.1M | -$1.1M | -$5.1M | -$2.2M | -$2.9M | -$6.0M | -$1.5M | -$1.9M |
| Net income | -$47.8M | -$990.9K | -$2.1M | -$1.1M | -$5.1M | -$2.2M | -$2.9M | -$6.0M | -$1.4M | -$6.3M |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.79 | $-0.03 | $-0.06 | $-0.03 | $-0.17 | $-0.07 | $-0.10 | $-0.20 | $-0.05 | $-0.23 |
| EBITDA | -$1.8M | -$1.0M | -$2.1M | -$1.1M | -$5.1M | -$2.2M | -$2.9M | -$6.0M | -$1.5M | -$1.9M |
| Operating cash flow | -$1.0M | -$1.8M | -$1.2M | -$927.3K | -$696.4K | -$863.1K | -$605.8K | -$1.0M | -$1.5M | -$1.9M |
| Free cash flow | -$1.0M | -$1.8M | -$1.2M | -$927.3K | -$696.4K | -$863.1K | -$605.8K | -$1.0M | -$1.5M | -$1.9M |
| Diluted shares | 60.8M | 34.4M | 34.4M | 32.4M | 30.0M | 29.8M | 29.7M | 29.6M | 29.6M | 29.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $5.2M | $5.6M | $7.3M | $7.3M | $754.3K | $403.0K |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $136.4K | $202.9K | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $5.4M | $5.8M | $7.3M | $7.4M | $829.6K | $491.2K |
| Total liabilities | $332.4K | $827.3K | $1.4M | $422.8K | $348.4K | $652.3K |
| Shareholders' equity | $5.0M | $5.0M | $5.9M | $7.0M | $481.2K | -$161.1K |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology